Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Fig. 1

Kaplan-Meier curves showing Etanercept (ETN) persistence in the Methotrexate (MTX) Assessment Cohort (n = 1681); a by JIA category (Log Rank Test p < 0.001); b by pattern of MTX use at ETN initiation (Log Rank p = 0.002); c by pattern of MTX use at ETN initiation in polyarticular JIA (Log Rank p = 0.09); d by pattern of MTX use at ETN initiation in spondyloarthritis patients (enthesitis related arthritis and psoriatic JIA, Log Rank p = 0.03). Included patients had at least 1 study visit 6 months after starting ETN. Combination therapy = MTX started concurrently with ETN; step-up therapy = MTX started > 1 month prior to ETN and continued > 1 month after ETN initiation; switchers included proximate switchers (MTX started> 1 month prior to ETN and discontinued within 1 month) and remote switchers prior to or after ETN) and remote switchers (MTX discontinued > 1 month prior to start of ETN); MTX add-on = MTX started > 1 month after starting ETN

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096